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Background: Constitutive activation of the PI3K-AKT-mTOR pathway (mTOR pathway) 
underlies megalencephaly in many patients. Yet, prevalence of the involvement of the 
PI3K-AKT-mTOR pathway in patients with megalencephaly remains to be elucidated, and molecular 
diagnosis is challenging. Elucidation of the molecular mechanisms underlying megalencephaly is 
crucial to determine the value of investigating therapeutic agents, such as rapamycin, in the context 
of mTOR pathway-associated megalencephaly. Here, we have successfully established a 
combination of genetic and biochemical methods for diagnosis of mTOR pathway-associated 
megalencephaly, and have attempted to delineate the clinical characteristics of the disorder. 
Methods: Thirteen patients with an increased head circumference and neurological symptoms 
participated in the study. To evaluate the activation of the mTOR pathway, we performed western 
blot analysis to determine the expression levels of phosphorylated S6 ribosomal protein (phospho-S6 
protein) in lymphoblastoid cell lines from nine patients. Multiplex targeted sequencing analysis for 
15 genes involved in the mTOR pathway was performed on 12 patients, and whole-exome 
sequencing was performed on one additional patient. Clinical features and MRI findings were also 
investigated. 
Results: We identified pathogenic mutations in six (AKT3, 1 patient; PIK3R2, 2 patients; PTEN, 3 
patients) of the 13 patients. Increased expression of phospho-S6 protein was demonstrated in all five 
mutation-positive patients in whom western blotting was performed, as well as in three 
mutation-negative patients. Developmental delay, dysmorphic facial features were observed in 
almost all patients. Syndactyly/polydactyly and capillary malformations were not observed, even in 
patients with AKT3 or PIK3R2 mutations. There were no common phenotypes or MRI findings 
among these patients. 
Conclusions: A combination of genetic and biochemical methods successfully identified mTOR 
pathway involvement in nine of 13 (approximately 70%) patients with megalencephaly, indicating a 
major contribution of the pathway to the pathogenesis of megalencephaly. Our study also disclosed 
the surprisingly broad clinical spectrum of the mTOR pathway associated megalencephaly. Our 
combined approach could be useful to identify patients who are suitable for future clinical trials 
using an mTOR inhibitor. 
